Oncology Strategy & Capital Advisory
AMAC® makes sure you collect accurately. Medsolve makes sure there is enough to collect in the first place.
AMAC® has protected reimbursement integrity for the last 44 years. Medsolve protects program economics. The two are complementary. In most programs under margin pressure, both are in play at the same time.
Many programs experience financial exposure long before reimbursement becomes the issue -- in capital plans that overpaid, proformas that were never stress-tested, or service line designs built on assumptions that were never pressure-checked at the executive level.
Medsolve works with oncology leadership to recalibrate those assumptions. Having operated on both sides of the vendor table across rural centers and large IDNs, we understand how agreements are structured, what financial sensitivities are often overlooked, and what a proforma must withstand when reviewed by a CFO.
In one recent engagement, Medsolve identified significant capital savings and an annual revenue opportunity for a radiation oncology program that had no reason to believe its financial model was exposed.
- $3M Capital Savings
- $1M Annual Revenue Opportunity
Where Medsolve Typically Engages
- Capital and vendor strategy alignment
- Financial modeling and proforma validation -- real ROI, not spreadsheet ROI
- Revenue and service line growth -- theranostics, benign disease, adaptive therapy
- AI and technology evaluation -- workflow fit, clinical impact, hype vs. reality
Who this is for: Oncology service line leaders, CFOs, and COOs navigating capital decisions under margin pressure.